ArticleFrontiers in pharmacology2026
Multi-omics integration and experimental validation reveal the mechanism of berberine against triple-negative breast cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking effective therapeutic options. Berberine (BBR), a natural isoquinoline alkaloid, has shown anti-tumor potential, but its systemic mechanism of action in TNBC has not been fully elucidated. Methods: This study adopted an integrated strategy combining network pharmacology, transcriptomic analysis, molecular docking, molecular dynamics simulation, and multi-level Results: A total of 182 common targets of BBR and TNBC were identified, with 12 genes, including SRC, STAT3, and EGFR, being identified as hub targets. Immune infiltration analysis indicated that BBR targets were associated with the tumor immune microenvironment. Single-cell sequencing showed that these targets are primarily enriched in tumor cells and macrophages, and molecular docking and dynamics simulations revealed that BBR has high affinity with SRC (-8.8 kcal/mol). Conclusion: BBR inhibits TNBC cell proliferation, induces apoptosis, weakens tumor stemness, and may regulate the tumor immune microenvironment through multi-target, multi-pathway synergistic effects. This study systematically reveals the integrative mechanism of BBR against TNBC, providing a theoretical basis for its development as a multi-target natural anti-tumor drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.